What is the KL-6 Biomarker?
KL-6 (Krebs von den Lungen-6) is a high-molecular-weight mucinous glycoprotein expressed on type 2 pneumocytes that serves as a serum biomarker for interstitial lung disease (ILD), though major international guidelines currently recommend against its routine use for distinguishing IPF from other ILDs due to insufficient diagnostic accuracy.
Biological Characteristics
KL-6 is a glycoprotein produced by type 2 alveolar pneumocytes and bronchiolar epithelial cells 1. When lung injury occurs—particularly in interstitial lung diseases—these cells become damaged or regenerate, releasing KL-6 into the bloodstream where it can be measured 1.
Clinical Context and Guideline Recommendations
The 2018 ATS/ERS/JRS/ALAT guidelines provide a strong recommendation AGAINST measuring serum KL-6 (along with MMP-7, SPD, and CCL-18) for distinguishing IPF from other ILDs 2. This strong recommendation reflects the guideline panel's conclusion that more than one-third of results would be incorrect, potentially leading to inappropriate therapy, delayed treatment, or unnecessary additional testing 2.
Key Limitation
The guidelines explicitly state that no studies compared clinical outcomes between patients who underwent KL-6 measurement versus those who did not, and the quality of evidence was rated as "very low" 2.
Diagnostic Performance
Despite guideline recommendations against routine use, research demonstrates KL-6 has measurable diagnostic utility:
- Sensitivity: 77-87% and specificity: 71-93% for detecting ILD at thresholds of 400-549 U/mL 3, 4, 5
- Normal reference range is typically below 500 U/mL 1
- KL-6 levels are significantly elevated in patients with active interstitial pneumonia (mean 1,497 U/mL) compared to inactive disease (441 U/mL) or controls (309 U/mL) 1
Disease-Specific Patterns
KL-6 levels vary substantially by ILD subtype 5:
- Pulmonary alveolar proteinosis: Markedly elevated (8,252 U/mL)
- CTD-ILD: Moderately elevated (1,347 U/mL)
- IPF: Moderately elevated (1,063 U/mL)
- Organizing pneumonia: Mildly elevated (468 U/mL)
- Sarcoidosis: Minimally elevated (359 U/mL)
Prognostic Value
Where KL-6 shows stronger clinical utility is in prognosis rather than diagnosis 6:
- Levels >1,000 U/mL predict significantly increased mortality risk in stable ILD patients (HR 2.95, p=0.0001) 7
- The 95% specificity threshold for poor outcome is 2,750 U/mL 7
- Serial measurements correlate with disease progression: baseline levels of 505 U/mL increasing to 1,150 U/mL at 12 months reflect worsening disease 3
- Higher KL-6 inversely correlates with FVC (p=0.019) and DLCO (p<0.001) 3
Prognostic Applications Supported by Evidence
The 2013 ATS/ERS statement acknowledges that elevated KL-6 is associated with rapidly declining lung function and reduced survival 6, suggesting potential value for identifying high-risk patients requiring closer monitoring or earlier intervention.
Clinical Pitfalls
Not recommended for differential diagnosis: The strong guideline recommendation reflects high false-positive and false-negative rates when attempting to distinguish IPF from other ILDs 2
Context-dependent interpretation: KL-6 diagnostic value is unaffected by immunosuppressive treatment in CTD-ILD patients, making it reliable across treatment states 8
Disease activity marker: KL-6 is more useful for assessing disease activity and treatment response than for initial diagnosis 4, 1
Geographic variation: KL-6 testing is more established in Asian countries (particularly Japan) than in Western practice, which may explain limited guideline endorsement despite research support
Practical Application Algorithm
For diagnosis: Do not order KL-6 to distinguish between ILD subtypes—follow guideline-recommended diagnostic pathways using HRCT patterns and multidisciplinary discussion 2.
For prognosis in established ILD:
- Measure baseline KL-6 at diagnosis
- If >1,000 U/mL: Patient at high risk for progression and mortality 7
- If >2,750 U/mL: Very high risk, consider aggressive monitoring and early treatment escalation 7
- Serial measurements every 3-6 months can track disease trajectory 3
For treatment monitoring in CTD-ILD: Serial KL-6 measurements showing declining levels correlate with treatment response and improving lung function 4, though this remains investigational rather than guideline-endorsed.